GB1309692A — N-substituted lactams

USPTO Abstract

1309692 N-Amidoaldyllactams UCB SA 19 April 1971 [13 Feb 1970] 6978/70 Addition to 1039113 Heading C2C Novel compounds of Formula I wherein X is a hydrogen atom or an alkyl, alkenyl or alkynyl radical containing 1 to 6 carbon atoms, p is a whole number of from 1 to 6, Y is a hydrogen atom or an alkyl, alkenyl or alkynyl radical containing 1 to 6 carbon atoms or a cycloalkyl radical and R<SP>1</SP> and R<SP>11</SP>, which may be the same or different, are hydrogen atoms or alkyl, alkenyl, alkynyl, cycloalkyl or aryl radicals or R<SP>1</SP> and R<SP>11</SP>, together with the nitrogen atom to which they are attached, form a heterocyclic radical which may contain further heteroatoms, with the proviso that at least one of the symbols X and Y is other than a hydrogen atom are prepared by one of the following methods: (a) a compound of formula wherein M is an alkali metal atom is reacted with a compound of formula (b) an ester of Formula IV where Alk is alkyl or (c) an acid chloride of Formula VI is reacted with the amine H.N.R<SP>1</SP>R<SP>11</SP>, and (d) an ammonium salt of formula is heated. Esters of Formula IV above are prepared by reacting the sodium derivative of the appropriate pyrrolidin-2-one with the appropriate alkyl haloalkylcarboxylate and optionally hydrolysed to the corresponding acids which may be converted into their ammonium salts and acid chlorides by reaction with ammonia or thionyl chloride respectively. Pharmaceutical compositions in conventional forms for oral, parenteral or rectal administration to be used in treatment of motion sickness, hyperkinesia, hypertonia, epilepsy and mnesic conditions comprise an above novel compound and an excipient.